-
Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
Ajai Chari, Albert Oriol, Amrita Y. Krishnan, Maria Del Carmen Martinez Chamorro, Luciano J. Costa, María‐Victoria Mateos, +9 more
50citations -
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Marc Steffen Raab, Niels Weinhold, Klaus Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, +23 more
47citations -
Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis2023 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James K. McCloskey, Francesca Palandri, Steffen Koschmieder, +18 more
42citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jacob P. Laubach, Jonathan L. Kaufman, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +22 more
24citations -
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Hervé Avet‐Loiseau, Pieter Sonneveld, Philippe Moreau, Fritz C. Offner, Vincent H. J. van der Velden, Denis Caillot, +25 more
21citations -
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, +21 more
21citations -
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, +26 more
19citations -
Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
Larysa Jessica Sanchez, Carolina Schinke, Amrita Y. Krishnan, Jesús G. Berdeja, Niels W.C.J. van de Donk, María‐Victoria Mateos, +19 more
18citations -
Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart, Per T Ljungman, Rafael de la Cámara, Gloria Tridello, Valentín Ortiz‐Maldonado, Álvaro Urbano-Ispizúa, +28 more
16citations -
Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study2024 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Efstathios Kastritis, Giovanni O. Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans Chulhee Lee, +24 more
15citations -
Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial
Antonio Maria Risitano, Austin Gladston Kulasekararaj, Alexander Roeth, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +29 more
14citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
Sonja Zweegman, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, +22 more
13citations -
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Andrew Charles Perkins, Vincent Ribrag, William E. Shomali, Rosa María Ayala, Claire N. Harrison, Stephen T. Oh, +2 more
12citations -
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study2021 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Raymond L. Comenzo, Giovanni O. Palladini, Efstathios Kastritis, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, +24 more
12citations -
Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, +14 more
12citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies
Saurabh Chhabra, Natalie S. Callander, Luciano J. Costa, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, +24 more
9citations -
Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
Lori Ann Leslie, Chan Yoon Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, +8 more
9citations